8-K: Medtronic Strengthens Board with Appointment of Renowned Healthcare Executive Dr. Joon Lee

Medtronic plc announced the expansion of its Board of Directors and the appointment of Dr. Joon Lee, CEO of Emory Healthcare, bringing extensive clinical, academic, and executive healthcare leadership to the company.

Summary

• Medtronic plc's Board of Directors increased its size from 10 to 11 members.
• Dr. Joon Lee was appointed as a new independent director, effective June 18, 2025.
• Dr. Lee will serve on the Science and Technology Committee and the Compensation and Talent Committee of the Board.
• He is eligible to receive an annual cash retainer and a director equity grant, consistent with the company's non-employee director compensation policy referenced in the August 9, 2024, Definitive Proxy Statement.
• Dr. Lee currently serves as the CEO of Emory Healthcare, Inc., which is described as the most comprehensive academic health system in Georgia, with $7.7 billion in yearly revenue, 12 hospitals, and over 29,000 employees.
• His distinguished career spans over 25 years at the University of Pittsburgh Medical Center (UPMC), where he held pivotal roles including Executive Vice President and President of Physician Services, Vice Dean of Clinical Affairs, Chief of the Division of Cardiology, and founding executive director of the UPMC Heart and Vascular Institute.
• From 2019 to 2021, Dr. Lee also served as Chief Medical Officer of UPMC Insurance Services, a $13 billion full-service health insurance division.

Sentiment

Score: 8

Explanation: The appointment of a highly qualified and experienced director like Dr. Joon Lee is a positive development for corporate governance and strategic direction, enhancing the board's capabilities. No negative information was presented.

Positives

• The appointment of Dr. Joon Lee, a highly respected interventional cardiologist and healthcare executive, significantly strengthens Medtronic's Board of Directors.
• Dr. Lee brings deep expertise in clinical research, academic leadership, and physician executive experience, with decades of broad leadership across the healthcare sector.
• His current role as CEO of Emory Healthcare, Inc., overseeing a $7.7 billion academic health system, demonstrates his capability in managing large and complex healthcare operations.
• His prior experience as Chief Medical Officer of UPMC Insurance Services, a $13 billion division, adds valuable insights into health insurance and integrated care models.
• Dr. Lee's passion for leveraging data and technology to improve patient and provider experiences aligns directly with Medtronic's mission to alleviate pain, restore health, and extend life.
• His addition to the Science and Technology Committee and the Compensation and Talent Committee will provide specialized expertise to key areas of the company's strategic development and governance.

Future Outlook

The appointment of Dr. Joon Lee is expected to further Medtronic's mission to alleviate pain, restore health, and extend life for patients worldwide by leveraging his insights on data and technology to improve patient and provider experiences.

Management Comments

• "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronics Board of Directors."
• "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with decades of broad leadership across healthcare."
• "He is passionate about leveraging data and technology to improve the patient and provider experienceinsights that will help us further our Mission to alleviate pain, restore health, and extend life for patients around the world."

Industry Context

Medtronic, a global leader in healthcare technology, continues to strengthen its leadership by bringing in top-tier talent like Dr. Joon Lee. This appointment reflects a broader industry trend of integrating clinical expertise with technological innovation and data-driven strategies to enhance patient care and operational efficiency within large healthcare systems.

Management Changes

Corporate Governance

Related Party Transactions

• No arrangements or understandings between Dr. Lee and any other persons pursuant to which he was selected as a director.
• Neither Dr. Lee nor any of his immediate family has been a party to any transaction or currently proposed transaction with the Company that is reportable under Item 404(a) of Regulation S-K.

Stakeholder Impact

• **Shareholders:** The addition of a highly experienced director like Dr. Lee is expected to strengthen corporate governance and strategic oversight, potentially leading to better long-term performance.
• **Employees:** Dr. Lee's appointment to the Compensation and Talent Committee suggests a focus on talent management and compensation strategies, which could benefit employees.
• **Customers/Patients:** Dr. Lee's passion for leveraging data and technology to improve patient and provider experience aligns with Medtronic's mission to alleviate pain, restore health, and extend life, potentially leading to enhanced product development and service delivery.

Next Steps

• Dr. Lee will serve on the Science and Technology Committee and the Compensation and Talent Committee of the Board.
• Dr. Lee will be eligible to receive an annual cash retainer and a director equity grant as per the company's non-employee director compensation policy.

Key Dates

Recommendation

Keywords

Medtronic, MDT, Board of Directors, Director Appointment, Corporate Governance, Healthcare Technology, Medical Devices, Joon Lee, Emory Healthcare, UPMC, SEC Filing, 8-K, Executive Appointment